Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need.
Location: United States, Massachusetts, Lexington
Employees: 51-200
Total raised: $79M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Foresite C... | foresiteca... |
| - | OrbiMed | orbimed.co... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.03.2020 | Series C | $56M | - |
| 08.01.2019 | Series B | $23M | - |
Mentions in press and media 19
| Date | Title | Description | Source |
| 05.03.2024 | Keros Therapeutics to Present at Leerink Partners 2024 Globa... | - | globenewsw... |
| 14.12.2021 | Corrected: Keros Therapeutics Presents Clinical Trial and Pr... | Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050... | marketscre... |
| 14.12.2021 | Corrected: Keros Therapeutics Presents Clinical Trial and Pr... | Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issui... | marketscre... |
| 13.12.2021 | Keros Therapeutics Presents Clinical Trial and Preclinical S... | Keros Therapeutics will be hosting a conference call and webcast today, December 13, 2021, at 4:01 p... | marketscre... |
| 13.12.2021 | Keros Therapeutics : Presents Clinical Trial and Preclinical... | Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program an... | marketscre... |
| 10.12.2021 | Keros Therapeutics : Investor Call Presentation | KER-050 Update 13 December 2021| CONFIDENTIAL Disclaimer Statements contained in this presentation r... | marketscre... |
| 04.11.2021 | Corporate Presentation November 2021 | Corporate Presentation November 2021 Disclaimer Statements contained in this presentation regarding ... | marketscre... |
| 22.06.2021 | Keros Therapeutics Announces Preliminary Results from its Ph... | LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS... | marketscre... |
| 22.06.2021 | Keros Therapeutics : KER-050 Update | KER-050 Update 23 June 2021 Disclaimer Statements contained in this presentation regarding matters t... | marketscre... |
| 07.05.2021 | KEROS THERAPEUTICS, INC. Keros Therapeutics : Corporate Pre... | Corporate Presentation May 2021 Disclaimer Statements contained in this presentation regarding matte... | marketscre... |
Show more